01 Shift Toward Orexin-Based and More Targeted Insomnia Therapies The sleeping pills market is shifting toward therapies that target specific sleep-regulation pathways rather than relying mainly on traditional sedative mechanisms. Dual orexin receptor antagonists (DORAs) are gaining attention because they act on the orexin system involved in wakefulness and sleep regulation. This is changing the competitive focus toward medicines that aim to improve sleep while addressing concerns associated with conventional hypnotics. As clinical evidence and regulatory experience expand, DORA therapies are becoming an increasingly important part of the sleeping pills market growth.For instance, in January 2025, Idorsia reported continued development of daridorexant through studies covering insomnia associated with conditions such as psychiatric and neurological disorders, menopause-related symptoms, and sleep apnea. The company also reported that daridorexant was available in multiple European and North American markets, supporting the broader development of orexin-based insomnia treatment.
02 Increasing Use of Combination and Digital Approaches for Insomnia Management Insomnia management is increasingly moving beyond medication alone toward treatment models that combine pharmacological therapy with behavioral interventions. Digital CBT-I, telehealth services, and software-based sleep programs can improve access to behavioral treatment and support patients alongside prescription medicines. This shift is influencing the sleeping pills market because medication providers increasingly operate within broader insomnia-care pathways rather than standalone drug treatment.For instance, in June 2025, the American Academy of Sleep Medicine released a public-comment draft guideline focused specifically on combining pharmacological treatment with behavioral-psychological treatment for chronic insomnia. The guideline addresses concurrent use of hypnotic medicines and interventions such as CBT-I, reflecting growing clinical interest in integrated treatment models.
01 Growing Recognition of Insomnia as a Common Clinical Condition The sleeping pills market is supported by greater recognition of insomnia as a clinically important disorder requiring appropriate diagnosis and treatment. More standardized assessment can identify patients who may benefit from pharmacological or behavioral interventions, expanding the addressable treatment population. Recent research also provides stronger evidence about the scale of the underlying condition, supporting continued demand for insomnia management.For instance, in May 2025, a meta-analysis published in the Journal of Sleep Research reviewed 47 studies and estimated the prevalence of insomnia disorder at 12.4% when standardized diagnostic interviews were used. The findings also highlighted the importance of consistent assessment methods for identifying insomnia.
01 Safety Concerns Continue to Limit Long-Term Use of Hypnotic Medicines Safety considerations remain a major restraint because some sleeping medicines can cause adverse effects that influence prescribing decisions and patient adherence. Concerns around sedation, dizziness, dependence, misuse, and other adverse reactions can encourage physicians to carefully evaluate treatment duration and alternatives. These issues can limit sustained use even when medications provide effective short-term symptom relief.For instance, in July 2025, a systematic review and network meta-analysis assessed adverse events associated with pharmacological treatments for insomnia in adults. The analysis found associations between several commonly used insomnia medicines and nervous-system or gastrointestinal adverse events, reinforcing the need to balance treatment benefits with safety considerations.
01 Expansion of Personalized Insomnia Treatment Based on Patient Characteristics Advances in insomnia research are creating opportunities for more individualized treatment strategies based on patient characteristics, comorbidities, symptom patterns, and treatment response. Better differentiation among insomnia subtypes can help clinicians select therapies more appropriately and may support the development of medicines designed for specific patient populations. This creates opportunities for pharmaceutical companies to expand beyond broad insomnia indications toward more targeted treatment approaches.For instance, in February 2025, researchers published findings in The Lancet examining different insomnia symptom profiles and their associations with health outcomes, reinforcing the potential value of distinguishing clinically meaningful patient characteristics when evaluating insomnia.
01 Maintaining Treatment Adherence Over Extended Insomnia Management Insomnia often requires ongoing management, creating challenges in maintaining patient adherence to prescribed treatment plans. Manufacturers and healthcare providers therefore need to support treatment continuity while ensuring that therapy remains appropriate as patients' sleep conditions change.For instance, in January 2025, a European expert consensus on switching or deprescribing hypnotic medicines for chronic insomnia was published, highlighting the need for structured treatment transitions and ongoing clinical management rather than relying on uninterrupted long-term use of a single sleeping medicine.
June 2026 Eli Lilly announced the acquisition of Centessa Pharmaceuticals for up to USD 7.8 billion, expanding its portfolio into orexin-targeted sleep-wake disorder therapies. The transaction strengthens Lilly's pipeline in sleep medicine and next-generation CNS therapeutics, including potential future insomnia treatments.
May 2026 Takeda Pharmaceutical submitted a New Drug Application (NDA) to the U.S. FDA for Oveporexton (TAK-861), an investigational oral orexin receptor agonist for narcolepsy type 1. While primarily indicated for narcolepsy, the program reinforces Takeda's strategic expansion in orexin-based sleep therapeutics relevant to the broader sleeping pills market.
February 2026 Alkermes plc completed the acquisition of Avadel Pharmaceuticals, strengthening its portfolio of sleep-wake disorder therapies and expanding its presence in innovative CNS and sleep medicine treatments.
January 2026 Takeda Pharmaceutical entered into a global licensing agreement with Nxera Pharma (formerly Sosei Heptares) to develop and commercialize orexin receptor-targeting therapies for sleep disorders, reinforcing its pipeline of next-generation sleep medicines.